Related Experiment Video
Updated: Jun 12, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells
Eduardo F Farias1, Kevin Petrie, Boris Leibovitch
1Department of Medicine, Division of Hematology and Oncology, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.
Abstract:
Sin3A/B is a master transcriptional scaffold and corepressor that plays an essential role in the regulation of gene transcription and maintenance of chromatin structure, and its inappropriate recruitment has been associated with aberrant gene silencing in cancer. Sin3A/B are highly related, large, multidomian proteins that interact with a wide variety of transcription factors and corepressor components, and we examined whether disruption of the function of a specific domain could lead to epigenetic reprogramming and derepression of specific subsets of genes. To this end, we selected the Sin3A/B-paired amphipathic alpha-helices (PAH2) domain based on its established role in mediating the effects of a relatively small number of transcription factors containing a PAH2-binding motif known as the Sin3 interaction domain (SID). Here, we show that in both human and mouse breast cancer cells, the targeted disruption of Sin3 function by introduction of a SID decoy that interferes with PAH2 binding to SID-containing partner proteins reverted the silencing of genes involved in cell growth and differentiation. In particular, the SID decoy led to epigenetic reprogramming and reexpression of the important breast cancer-associated silenced genes encoding E-cadherin, estrogen receptor alpha, and retinoic acid receptor beta and impaired tumor growth in vivo. Interestingly, the SID decoy was effective in the triple-negative M.D. Anderson-Metastatic Breast-231 (MDA-MB-231) breast cancer cell line, restoring sensitivity to 17beta-estradiol, tamoxifen, and retinoids. Therefore, the development of small molecules that can block interactions between PAH2 and SID-containing proteins offers a targeted epigenetic approach for treating this type of breast cancer that may also have wider therapeutic implications.
Insights
Targeting the Sin3A/B paired amphipathic alpha-helices (PAH2) domain with a Sin3 interaction domain (SID) decoy reactivates silenced cancer genes. This epigenetic reprogramming impairs tumor growth and restores drug sensitivity in breast cancer models.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Sin3A/B proteins are crucial transcriptional corepressors involved in gene silencing and chromatin structure.
- Aberrant recruitment of Sin3A/B is linked to gene silencing in various cancers.
- The paired amphipathic alpha-helices (PAH2) domain of Sin3A/B mediates interactions with transcription factors via the Sin3 interaction domain (SID).
Purpose of the Study:
- To investigate if disrupting the Sin3A/B PAH2 domain function can induce epigenetic reprogramming and gene derepression.
- To evaluate the therapeutic potential of targeting the PAH2-SID interaction in breast cancer.
Main Methods:
- Utilized a Sin3 interaction domain (SID) decoy to interfere with PAH2-SID binding in human and mouse breast cancer cells.
- Assessed the impact of SID decoy on gene expression, epigenetic modifications, and tumor growth in vivo.
- Tested the efficacy of the SID decoy in triple-negative breast cancer cell lines and its effect on drug sensitivity.
Main Results:
- Targeted disruption of Sin3A/B function via the SID decoy reversed silencing of genes critical for cell growth and differentiation.
- The SID decoy induced epigenetic reprogramming and reexpression of E-cadherin, estrogen receptor alpha, and retinoic acid receptor beta.
- Tumor growth was impaired in vivo, and the SID decoy restored sensitivity to hormonal therapies and retinoids in MDA-MB-231 cells.
Conclusions:
- Interfering with the PAH2-SID interaction represents a viable epigenetic strategy for breast cancer treatment.
- Small molecules blocking PAH2-SID interactions could offer a targeted therapeutic approach for breast cancer.
- This approach may have broader implications for treating cancers driven by aberrant gene silencing.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Abnormal Proliferation
Somatic to iPS Cell Reprogramming
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
